tiprankstipranks
Trending News
More News >
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
US Market

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

Compare
427 Followers
See the Price Targets and Ratings of:

NRIX Analyst Ratings

Strong Buy
15Ratings
Strong Buy
13 Buy
2 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Nurix
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$29.43
▲(130.28%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $29.43 with a high forecast of $36.00 and a low forecast of $16.00. The average price target represents a 130.28% change from the last price of $12.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","16":"$16","23":"$23","30":"$30","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,16,23,30,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,13.975384615384616,15.810769230769232,17.646153846153847,19.481538461538463,21.316923076923075,23.152307692307694,24.987692307692306,26.823076923076925,28.658461538461538,30.493846153846153,32.32923076923077,34.16461538461539,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,13.47,14.8,16.13,17.46,18.79,20.119999999999997,21.45,22.78,24.11,25.439999999999998,26.77,28.099999999999998,{"y":29.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,12.436923076923078,12.733846153846155,13.03076923076923,13.327692307692308,13.624615384615385,13.921538461538463,14.21846153846154,14.515384615384615,14.812307692307693,15.10923076923077,15.406153846153845,15.703076923076924,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$29.43Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NRIX
TipRanks AITipRanks
Not Ranked
TipRanks
$12.5
Hold
-2.19%
Downside
Reiterated
06/03/25
The overall score reflects significant financial performance challenges and a weak valuation, tempered by positive corporate developments and some technical momentum. The company's strong equity position and recent board appointment provide some support, but the lack of profitability and cash flow issues remain major concerns.
Leerink Partners Analyst forecast on NRIX
Faisal KhurshidLeerink Partners
Leerink Partners
$16
Hold
25.20%
Upside
Reiterated
06/03/25
Leerink Partners Sticks to Its Hold Rating for Nurix Therapeutics (NRIX)
Truist Financial Analyst forecast on NRIX
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
06/03/25
Truist Financial Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Wells Fargo Analyst forecast on NRIX
Derek ArchilaWells Fargo
Wells Fargo
$25
Buy
95.62%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Dexcom (NASDAQ: DXCM) and Immunovant (NASDAQ: IMVT)
Stifel Nicolaus Analyst forecast on NRIX
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$36$35
Buy
173.87%
Upside
Reiterated
06/02/25
Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating
Needham Analyst forecast on NRIX
Gil BlumNeedham
Needham
$27
Buy
111.27%
Upside
Reiterated
06/02/25
Analyst Recommends 'Buy' for Nurix Therapeutics Amid Strong Endorsement and Promising STAT6 Program
Oppenheimer Analyst forecast on NRIX
Matthew BieglerOppenheimer
Oppenheimer
$32
Buy
150.39%
Upside
Reiterated
06/02/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Barclays Analyst forecast on NRIX
Peter LawsonBarclays
Barclays
$31
Buy
142.57%
Upside
Reiterated
05/23/25
Barclays Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Piper Sandler Analyst forecast on NRIX
Biren AminPiper Sandler
Piper Sandler
$35
Buy
173.87%
Upside
Reiterated
05/07/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on NRIX
Terence FlynnMorgan Stanley
Morgan Stanley
$17
Hold
33.02%
Upside
Reiterated
04/10/25
Cautious Outlook on Nurix Therapeutics Amid Promising Pipeline and Development Uncertainties
UBS
$35$30
Buy
134.74%
Upside
Reiterated
04/10/25
Nurix Therapeutics price target lowered to $30 from $35 at UBSNurix Therapeutics price target lowered to $30 from $35 at UBS
Lucid Capital Analyst forecast on NRIX
Christopher LiuLucid Capital
Lucid Capital
$35$36
Buy
181.69%
Upside
Reiterated
04/09/25
Nurix (NRIX) PT Raised to $36 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $35.00) while maintaining a Buy rating.
Stephens
$31$30
Buy
134.74%
Upside
Reiterated
04/09/25
Nurix (NRIX) PT Lowered to $30 at StephensStephens analyst Sudan Loganathan lowered the price target on Nurix (NASDAQ: NRIX) to $30.00 (from $31.00) while maintaining a Overweight rating.
RBC Capital Analyst forecast on NRIX
Gregory RenzaRBC Capital
RBC Capital
$27
Buy
111.27%
Upside
Reiterated
04/08/25
Nurix Therapeutics (NRIX) Receives a New Rating from RBC Capital
BTIG
$35
Buy
173.87%
Upside
Reiterated
04/08/25
Promising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NRIX
TipRanks AITipRanks
Not Ranked
TipRanks
$12.5
Hold
-2.19%
Downside
Reiterated
06/03/25
The overall score reflects significant financial performance challenges and a weak valuation, tempered by positive corporate developments and some technical momentum. The company's strong equity position and recent board appointment provide some support, but the lack of profitability and cash flow issues remain major concerns.
Leerink Partners Analyst forecast on NRIX
Faisal KhurshidLeerink Partners
Leerink Partners
$16
Hold
25.20%
Upside
Reiterated
06/03/25
Leerink Partners Sticks to Its Hold Rating for Nurix Therapeutics (NRIX)
Truist Financial Analyst forecast on NRIX
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
06/03/25
Truist Financial Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Wells Fargo Analyst forecast on NRIX
Derek ArchilaWells Fargo
Wells Fargo
$25
Buy
95.62%
Upside
Reiterated
06/02/25
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Dexcom (NASDAQ: DXCM) and Immunovant (NASDAQ: IMVT)
Stifel Nicolaus Analyst forecast on NRIX
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$36$35
Buy
173.87%
Upside
Reiterated
06/02/25
Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating
Needham Analyst forecast on NRIX
Gil BlumNeedham
Needham
$27
Buy
111.27%
Upside
Reiterated
06/02/25
Analyst Recommends 'Buy' for Nurix Therapeutics Amid Strong Endorsement and Promising STAT6 Program
Oppenheimer Analyst forecast on NRIX
Matthew BieglerOppenheimer
Oppenheimer
$32
Buy
150.39%
Upside
Reiterated
06/02/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Barclays Analyst forecast on NRIX
Peter LawsonBarclays
Barclays
$31
Buy
142.57%
Upside
Reiterated
05/23/25
Barclays Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Piper Sandler Analyst forecast on NRIX
Biren AminPiper Sandler
Piper Sandler
$35
Buy
173.87%
Upside
Reiterated
05/07/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on NRIX
Terence FlynnMorgan Stanley
Morgan Stanley
$17
Hold
33.02%
Upside
Reiterated
04/10/25
Cautious Outlook on Nurix Therapeutics Amid Promising Pipeline and Development Uncertainties
UBS
$35$30
Buy
134.74%
Upside
Reiterated
04/10/25
Nurix Therapeutics price target lowered to $30 from $35 at UBSNurix Therapeutics price target lowered to $30 from $35 at UBS
Lucid Capital Analyst forecast on NRIX
Christopher LiuLucid Capital
Lucid Capital
$35$36
Buy
181.69%
Upside
Reiterated
04/09/25
Nurix (NRIX) PT Raised to $36 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $35.00) while maintaining a Buy rating.
Stephens
$31$30
Buy
134.74%
Upside
Reiterated
04/09/25
Nurix (NRIX) PT Lowered to $30 at StephensStephens analyst Sudan Loganathan lowered the price target on Nurix (NASDAQ: NRIX) to $30.00 (from $31.00) while maintaining a Overweight rating.
RBC Capital Analyst forecast on NRIX
Gregory RenzaRBC Capital
RBC Capital
$27
Buy
111.27%
Upside
Reiterated
04/08/25
Nurix Therapeutics (NRIX) Receives a New Rating from RBC Capital
BTIG
$35
Buy
173.87%
Upside
Reiterated
04/08/25
Promising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

1 Month
xxx
Success Rate
8/11 ratings generated profit
73%
Average Return
+7.58%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +7.58% per trade.
3 Months
xxx
Success Rate
9/11 ratings generated profit
82%
Average Return
+32.22%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +32.22% per trade.
1 Year
Derek ArchilaWells Fargo
Success Rate
7/11 ratings generated profit
64%
Average Return
+66.42%
reiterated a buy rating 7 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +66.42% per trade.
2 Years
xxx
Success Rate
15/19 ratings generated profit
79%
Average Return
+38.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +38.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
19
12
15
17
21
Buy
5
3
1
1
2
Hold
0
2
5
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
17
21
23
27
In the current month, NRIX has received 23 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 29.43.
Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.71 with a range of -$0.96 to -$0.49. The previous quarter’s EPS was -$0.67. NRIX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.
Next quarter’s earnings estimate for NRIX is -$0.71 with a range of -$0.96 to -$0.49. The previous quarter’s EPS was -$0.67. NRIX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $16.27M with a range of $0.00 to $33.64M. The previous quarter’s sales results were $18.45M. NRIX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.
Next quarter’s sales forecast for NRIX is $16.27M with a range of $0.00 to $33.64M. The previous quarter’s sales results were $18.45M. NRIX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year NRIX has Outperformed its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Nurix Therapeutics’s 12-month average price target is 29.43.
    What is NRIX’s upside potential, based on the analysts’ average price target?
    Nurix Therapeutics has 130.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NRIX a Buy, Sell or Hold?
          Nurix Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Nurix Therapeutics’s price target?
            The average price target for Nurix Therapeutics is 29.43. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $36.00 ,the lowest forecast is $16.00. The average price target represents 130.28% Increase from the current price of $12.78.
              What do analysts say about Nurix Therapeutics?
              Nurix Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of NRIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis